Generated by AI
Dyadic International, Inc. is a biotechnology company focused on scalable protein production for non-pharmaceutical applications. Through its proprietary C1 and Dapibus expression platforms, Dyadic develops and commercializes precision-engineered proteins and enzymes used in life sciences, food and nutrition, and industrial biotechnology. Its technology is designed to support the efficient manufacture of recombinant, animal-free inputs that can be sold directly or licensed to partners across multiple markets. The company’s current business centers on producing functional proteins for customers seeking flexible, cost-effective biomanufacturing solutions in areas such as specialty ingredients, enzyme development, and other bioindustrial uses. Dyadic International, Inc. is headquartered in Jupiter, Florida, and operates as a global biotechnology platform company serving commercial and research-oriented applications.
Website1044 North U.S. Highway One
Jupiter, FL, 33477-5094
United States
The latest articles about DYAI.
Dyadic International Inc (DYAI) posted an 80% productivity gain in its animal-free transferrin program and began product shipments, but flat revenue and liquidity concerns cloud the outlook.
Summary of Jul 21's posts. Generated by AI.
Summary of Aug 25's posts. Generated by AI.
Summary of Aug 16's posts. Generated by AI.
Summary of Jun 6's posts. Generated by AI.
Investors talking about DYAI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.